In in vitro breast cancer, the proliferation and anti-tumor efficacy of biCAR-T cells depend on combinational targeting of HER2 and MUC1 simultaneously with CD3z and other co-costimulatory molecules in one T cell. This evidence concerns the gene ERBB2 and neoplasm.